Trxade Group logo
Trxade Group MEDS

Quarterly report 2025-Q3
added 11-12-2025

report update icon

Trxade Group Income Statement 2011-2025 | MEDS

Annual Income Statement Trxade Group

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

5.09 M 260 K 16.5 M 41.9 M 7.28 M 3.08 M 2.16 M 2.1 M 5.22 M 8.45 M - - -

Shares

764 K 565 K 8.14 M 7.57 M 5.83 M 5.83 M 5.68 M 5.26 M 5.22 M 4.97 M - - -

Historical Prices

6.66 0.46 2.03 5.53 1.25 0.528 0.38 0.4 1 1.7 - - -

Net Income

-17.8 M -3.47 M -5.32 M -2.54 M -284 K 9.04 K 289 K -2.76 M -1.12 M -2.01 M -2.09 M - -

Revenue

8.27 M 10.3 M 9.89 M 17.1 M 7.44 M 3.83 M 2.93 M 2.48 M 2.91 M 1.5 M 956 K - -

Cost of Revenue

5.67 M 4.73 M 5.14 M 11.4 M 2.57 M 449 K - - - - - - -

Gross Profit

2.6 M 5.52 M 4.75 M 5.71 M 4.87 M 3.38 M - 2.47 M 2.72 M 1.06 M 11.8 K - -

Operating Income

-7.26 M -2.92 M -5.29 M -2.51 M 125 K -87.6 K 395 K -1.01 M -137 K -1.43 M -2.08 M - -

Interest Expense

1.2 M 336 K 23.6 K 29.4 K 53.2 K 57.5 K 157 K 152 K 120 K 4.15 K 7.28 K - -

EBITDA

-7.24 M -2.9 M -5.28 M -1.68 M -48.3 K 66.6 K 446 K -2.61 M -133 K -1.43 M -2.08 M - -

Operating Expenses

9.86 M 8.44 M 10 M 7.49 M 4.38 M 3.3 M 2.27 M 3.45 M 4.05 M 2.49 M 2.1 M - -

General and Administrative Expenses

2.79 M 1.69 M 1.9 M 7.49 M 4.38 M 2.35 M 2.27 M - - - - - -

All numbers in USD currency

Quarterly Income Statement Trxade Group

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

19 M 14.1 M 9.43 M 8.75 M 2.37 M 1.41 M 1.04 M 905 K 771 K 681 K 10.1 M 626 K 550 K 545 K 8.18 M 8.17 M 8.16 M 8.12 M 8.09 M 8.09 M 8.06 M 7.58 M 6.97 M 6.54 M 5.75 M 5.62 M 5.56 M 5.55 M 32.1 M 32 M 32 M 32 M 32 M 32 M 31.9 M 31.7 M 31.6 M 31.5 M 31.4 M 31.4 M 31.3 M 31.3 M 31.3 M 31.3 M 29.6 M 29.4 M 29.1 M 28.8 M 27.5 M - - - - - - - - - -

Net Income

-3.61 M -6.72 M -3.06 M - -3.18 M -1.83 M 21.2 M - -3.53 M -1.97 M -678 K - -503 K -1.11 M -966 K - -1.3 M -2.58 M -652 K - 138 K -543 K 180 K - 27.6 K 58 K 125 K - 94.2 K 20.5 K 82.3 K - 76.2 K -6.84 K 79.7 K - -843 K -1.1 M -372 K - -124 K -54.4 K -444 K - -352 K -301 K -922 K - -284 K -184 K - - - - - - - - -

Revenue

590 K - 10.3 K - 64.9 K 18.7 K - - 392 K 367 K 2.25 M - 2.06 M 3.28 M 3.24 M - 2.55 M 1.9 M 3.05 M - 6.33 M 6.59 M 2.2 M - 2.31 M 1.92 M 1.51 M - 847 K 838 K 853 K - 736 K 705 K 746 K - 611 K 588 K 645 K - 1.64 M 1.17 M 696 K - 373 K 288 K 244 K - 323 K 255 K - - - - - - - - -

Cost of Revenue

15.4 K - 9.58 K - 61 K 19.4 K - - 353 K 606 K 691 K - 683 K 2.11 M 1.9 M - 4 M 1.06 M 1.67 M - 4.4 M 4.59 M 563 K - 1 M 753 K 366 K - 2.34 K - - - - - - - - 770 - - - - - - - - - - - - - - - - - - - - -

Gross Profit

575 K - 673 - 3.88 K -703 - - 39.6 K 67.1 K 1.56 M - 1.37 M 1.17 M 1.34 M - 1.28 M 841 K 1.38 M - 1.93 M 2 M 1.64 M - 1.31 M 1.16 M 1.15 M - 845 K 838 K 853 K - 736 K 705 K 746 K - 611 K 588 K 629 K - 937 K 785 K 466 K - 296 K 237 K 97.4 K - -45.3 K 132 K - - - - - - - - -

Operating Income

-4.36 M -5.16 M -3.57 M - -3.5 M -1.5 M -5.49 M - -762 K -600 K -347 K - -219 K -1.1 M -969 K - -1.3 M -2.57 M -644 K - 146 K -535 K 188 K - 178 K 133 K 172 K - 91.8 K 31.4 K 98.7 K - 89.6 K 48.8 K 141 K - -245 K -578 K -130 K - -76.6 K -26.4 K -443 K - -350 K -300 K -345 K - -283 K -184 K - - - - - - - - -

Interest Expense

- - - - - - - - 252 K 181 K 62.4 K - 130 K 9.16 K 1.36 K - 5.62 K 8.69 K 7.26 K - 7.43 K 7.31 K 7.92 K - 13.4 K 15.9 K 17.6 K - 12.6 K 10.9 K 16.5 K - 30.9 K 44.1 K 61.7 K - 50.3 K 29.8 K 40.9 K - 47.2 K 27.9 K 969 - 2.06 K 991 1.06 K - 851 563 - - - - - - - - -

EBITDA

- - -3.57 M - - - -5.49 M - - - -345 K - -207 K -1.1 M -965 K - -1.29 M -2.57 M -643 K - 150 K -533 K 189 K - 182 K 135 K 173 K - 91.8 K 31.4 K 98.7 K - 89.6 K 48.8 K 141 K - -239 K -578 K -130 K - -72.8 K -24 K -441 K - -346 K -298 K -343 K - -280 K -182 K - - - - - - - - -

Operating Expenses

4.94 M 5.16 M 3.57 M - 3.5 M 1.49 M 5.49 M - 801 K 667 K 1.9 M - 1.59 M 2.27 M 2.3 M - 2.58 M - 2.03 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

2.17 M 2.93 M 1.36 M - 169 K 415 K 4.7 M - 66.9 K 170 K 377 K - 230 K 547 K 651 K - 917 K 2.19 M 448 K - 1.78 M 2.54 M 1.45 M - 1.13 M 1.03 M 975 K - 753 K 806 K 754 K - 646 K 656 K 604 K - 856 K 1.17 M 759 K - 1.01 M 812 K 908 K - 645 K 537 K 442 K - 238 K 316 K - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Trxade Group (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Pharmaceutical retailers industry

Issuer Price % 24h Market Cap Country
Аптеки 36.6 Аптеки 36.6
APTK
- - - russiaRussia
China Jo-Jo Drugstores, Inc. China Jo-Jo Drugstores, Inc.
CJJD
- -5.59 % $ 49.9 M chinaChina
Greenlane Holdings Greenlane Holdings
GNLN
$ 2.99 -3.24 % $ 22.5 M usaUSA
BOQI International Medical BOQI International Medical
BIMI
- 6.33 % $ 5.86 M chinaChina
PetMed Express PetMed Express
PETS
$ 3.02 70.69 % $ 62.2 M usaUSA
LifeMD LifeMD
LFMD
$ 3.45 -4.43 % $ 117 M usaUSA
Rite Aid Corporation Rite Aid Corporation
RAD
- - $ 35.5 M usaUSA
111 111
YI
$ 3.7 -4.15 % $ 636 M chinaChina
Walgreens Boots Alliance Walgreens Boots Alliance
WBA
- - $ 10.3 B usaUSA